W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > December 2007

Might be interesting to approach these folks about making their KB available in RDF

From: Alan Ruttenberg <alanruttenberg@gmail.com>
Date: Thu, 13 Dec 2007 06:45:44 -0500
To: public-semweb-lifesci@w3.org
Message-Id: <AD56C751-E254-4323-B0C6-301490733E0D@gmail.com>


Begin forwarded message:

> From: "New Medicine Oncology KnowledgeBASE"  
> <gtcbio@lifescienceshome.com>
> Date: December 12, 2007 5:11:48 PM EST
> Subject: Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway  
> Generated nearly $5 billion
> Reply-To: "New Medicine Oncology KnowledgeBASE"  
> <carrie.langton@gtcbio.com>
>
> Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone  
> Generated Global Sales of nearly $5 billion in the First Nine  
> Months of 2007
>
> Currently, Over 370 Agents are in Active Clinical Development,  
> Addressing Over 190 Targets
>
> LAKE FOREST, Calif., Nov. 27 /PRNewswire/ -- Six ErbB (EGFr/HEr2)- 
> pathway inhibitors, marketed for the treatment of several major  
> solid tumor indications, generated global sales of $4,964.4 million  
> in the first 9 months of 2007, almost surpassing the $5,160 million  
> total revenues of these agents in 2006.
>
> Despite this unprecedented market success and the acceptance of  
> targeted therapies in oncology practice, many challenges remain  
> unfulfilled.  One key problem of currently approved agents is the  
> relatively marginal benefits they provide; median progression-free  
> survival (PFS) and overall survival (OS) are extended only by a few  
> months.  However, aggressive efforts to overcome current  
> limitations are providing unique opportunities in this field.
>
> Currently, all targeted therapeutics, both approved and novel are  
> under evaluation almost exclusively in combination with approved  
> cytotoxic agents.  Because cytotoxics remain the treatment mainstay  
> for adjuvant, neoadjuvant and advanced/metastatic disease,  
> opportunities still exist for the development of more effective,  
> less toxic alternatives.
>
> Targeted therapeutics are also under investigation in combination  
> with each other, in efforts to simultaneously inhibit additional or  
> compensating pathways, or to maximize effectiveness against a  
> single target by combining drugs acting by different mechanisms,  
> e.g., receptor tyrosine kinase (RTK) inhibitors and monoclonal  
> antibodies (MAb), against the same target.  Also, multitargeted  
> inhibitors are in development against different targets in the same  
> or different pathways hypothesized to act in concert in malignancy.
>
> The commercial success of the ErbB inhibitors and other targeted  
> anticancer agents has stimulated R&D in this field.  More than 370  
> drugs have entered clinical trials, with many having already  
> reached phase II (n=183) or phase III (n=43) stages of  
> development.   In addition hundreds of agents are in preclinical  
> development.  Their mechanisms of action are wide ranging,  
> targeting some of the more than 1,000 different molecular markers  
> implicated in malignancy.
>
> Molecularly targeted agents in development are ushering in the age  
> of personalized medicine.  There is pressing need for better  
> diagnostic, theragnostic, prognostic, pharmacogenomic and disease  
> monitoring methodologies for patient selection and optimized  
> treatment.
>
> The source, mechanisms of action, and preclinical and clinical  
> status, including interim and final trial results, of all of these  
> agents are described in detail in New Medicine’s Oncology  
> KnowledgeBASE (nm/OK).  By interrogating nm/OK users may:
>
> •	Identify novel agents addressing either a single target or  
> multiple pathways/targets and review in detail their preclinical  
> and clinical status
>
> •	Locate targeted agents in clinical trials in combination with  
> specific approved cytotoxic agents or classes of such drugs, i.e.  
> platinum-based agents, taxanes, etc.
>
> •	Obtain comprehensive, cited data on over 1,000 targets that may  
> be applicable as diagnostic, theragnostic, prognostic,  
> pharmacogenomic, disease monitoring and/or therapeutic targets in  
> cancer
>
> •	Obtain interim and final results of combination trials of  
> approved anticancer agents, by cancer indication, target, clinical  
> development status, etc.
>
> •	Obtain detailed records of anticancer targets by 100 different  
> cancer indications, and many subtypes such as non-small cell lung  
> cancer (nsclc), triple receptor-negative breast cancer,  
> glioblastoma multiforme (GBM), etc.
>
> •	View detailed records of drugs in development for several hundred  
> highly specific clinical indications, i.e. advanced or metastatic  
> disease, adjuvant or neoadjuvant treatment, first line or second  
> line treatment
>
> •	Obtain detailed preclinical and/or clinical pipelines of over  
> 1,000 developers of anticancer agents, including detailed profiles  
> of the companies and their affiliates
>
> •	Identify licensing opportunities
>
> •	Assess global market opportunities based on revenues of approved  
> drugs and the epidemiology of specific cancer indications
>
> •	Create proprietary ‘saved searches’ to monitor developments in a  
> pre-selected group of agents chosen by specific shared parameters,  
> i.e., targets, delivery systems, mechanism of action, cancer  
> indication, clinical indication, stage of development, etc.
>
> Contact us for an online demonstration of nm|OK.
>
> Contact: Katie Siafaca
>      Tel: (949) 830-0448;
>      Fax: (949) 830-0887
>      E-mail: info@newmedinc.com
>      http://www.newmedinc.com
>      http://nmok.net
>      http://nmok.net/oksite/samprecords.html
>
>
>  SOURCE New Medicine's Oncology KnowledgeBASE
>
Received on Thursday, 13 December 2007 11:46:06 UTC

This archive was generated by hypermail 2.3.1 : Wednesday, 7 January 2015 14:52:34 UTC